Occasional review

A role for capsaicin sensitive, tachykinin containing nerves in chronic coughing and sneezing but not in asthma: a hypothesis

J-A Karlsson

Sensory nerves with endings in the airway mucosa mediate respiratory protective reflexes such as coughing, sneezing, mucus secretion, and bronchoconstriction, which are common symptoms of airway disease. Studies in experimental animals suggest that these reflexes have unique afferent pathways, though these have been difficult to identify in man. One pharmacological tool that is increasingly used in studies of neural reflexes is capsaicin, the pungent agent of hot peppers. Capsaicin seems to excite rather selectively a population of tachykinin peptide containing, chemosensitive afferent nerves.

In rodent airways capsaicin produces severe bronchoconstriction and a pronounced inflammatory response, which seems to be mediated by substance P, neurokinin A, and possibly other tachykinin peptides. Tachykinins contract human bronchi in vitro and produce bronchoconstriction when inhaled by asthmatic subjects. The density of substance P immunoreactive nerves and expression of the neurokinin, receptor gene have been reported to be increased in the asthmatic lung. Consequently neuropeptide release, via an axon reflex, has been proposed to be particularly important in the pathology of asthma. The proinflammatory effects so apparent in rodents, however, cannot be reproduced even when high doses of capsaicin are repeatedly inhaled by normal or asthmatic subjects and capsaicin sensitive nerves seem unlikely therefore to have a major role in asthma. Instead, experimental and clinical data indicate that their most important function in the human respiratory tract is to mediate protective reflexes. The hypothesis now is that hyperreactivity in these afferent nerves—that is, sensory hyperresponsiveness—contributes to respiratory symptoms in patients with chronic non-productive cough and non-allergic chronic rhinitis.

Neurokinin containing sensory nerves and the axon reflex

Substance P was first found in guinea pig airway tissue but we now know that it is also present in many other species, including man. Substance P belongs to a family of structurally closely related peptides, including neurokinin A, neurokinin B, neuropeptide K, and neuropeptide gamma, which are derived from at least two different preprotachykinin genes. These tachykinins, and calcitonin gene related peptide, are present in a population of non-mylinated capsaicin sensitive afferent nerves.

Capsaicin induced neuropeptide release is preceded by increased cation permeability over the cell membrane. In larger concentrations capsaicin is neurotoxic and rapidly causes death of nerve cells. The tachykinins act on neurokinin 1, 2, or 3 receptors (which have highest affinity for substance P, neurokinin A, and neurokinin B, respectively), located on airway and vascular smooth muscle, submucosal glands, parasympathetic nerves, and airway epithelium. In guinea pigs and rats tachykinin peptides produce bronchoconstriction, vasodilatation, plasma protein leakage from the tracheobronchial microcirculation, mucus secretion, and facilitation of cholinergic neurotransmission. These effects are mimicked by capsaicin, suggesting an important sensory efferent role for these nerves. Thus in rodent airways neuropeptides released from capsaicin sensitive sensory neurons, presumably via an axon reflex, have pronounced bronchoconstrictor and proinflammatory actions.

Interestingly, the most obvious responses to intravascular administration of tachykinins or capsaicin in the sheep, pig, dog and cat are a vasodilator response in the tracheobronchial circulation and mucus secretion. When present, airway smooth muscle contraction in rat, rabbit, ferret, and dog is largely mediated through parasympathetic cholinergic pathways. In the cat capsaicin produces a reflex bronchodilatation. Furthermore, plasma protein extravasation has not been observed in cat or dog airways. Hence the characteristic bronchoconstrictor and proinflammatory effects have not been confirmed in non-rodent animal species.

Sensory neuropeptides in human airways

Human bronchi are contracted by tachykinin peptides in vitro, neurokinin A—but not substance P—being more potent than methacholine and histamine. It has been more difficult to show bronchoconstriction in vivo. Maximum doses of inhaled substance P are without effect on airway tone and when infused intravenously a predominantly cardiovascular response was obtained. Neurokinin A is 10 times more potent than
A role for capsaicin sensitive, tachykinin containing nerves in chronic coughing and sneezing but not in asthma: a hypothesis

Substance P in vitro, which may explain why airways obstruction was induced when a large dose was inhaled by asthmatic subjects. The bronchoconstriction was inhibited partly by nedocromil sodium and partly by an antimuscarinic agent, indicating that neurokinin A did not act directly on the smooth muscle. In healthy and asthmatic subjects inhaled capsaicin caused only transient bronchoconstriction (for under a minute) which depends on a parasympathetic cholinergic reflex. Endogenous tachykinins, if released, are therefore unlikely to have any noticeable effects on airway tone in vivo.

It has been speculated that the shedding of epithelium that occurs in severe asthma and upper respiratory tract viral infections reduces airway neutral endopeptidase activity, which is present in the bronchial mucosa and is the major proteolytic enzyme for tachykinins. Consequently the "braking" mechanism would be absent in asthmatic subjects and endogenous tachykinins would be able to exert their proinflammatory effects uninhibited. Thiorphan, a neutral endopeptidase inhibitor, would thus be expected to increase basal tone (by potentiating the effect of endogenous tachykinins) and augment the effects of inhaled peptides in healthy subjects. In asthmatic subjects on the other hand no effect would be expected if neutral endopeptidase is absent.

Inhaled thiorphan, however, was found to have no effect on basal tone but to potentiate inhaled neurokinin A to the same degree in healthy and asthmatic subjects. Nichol and coworkers studied the neutral endopeptidase inhibitor acetermin in reflex bronchoconstriction induced by inhaled metabisulphite in asthmatic subjects. Metabisulphite acts partly via a non-cholinergic mechanism, but its effect was not altered by acetermin (though weal and flare induced by substance P were significantly potentiated in the same subjects). These experiments were conducted in subjects with mild asthma, and if shedding of epithelium is proportional to the severity of the disease, the effect could be more pronounced in severe asthma. The present data support the view that endogenous tachykinins are not important for regulation of bronchial tone in human airways in vivo. Clinical studies with the recently developed potent non-peptide neurokinin receptor antagonists, however, will provide further information on the role of tachykinin peptides in man.

The effects of local application of tachykinins and capsaicin on nasal air flow, leakage of plasma proteins, and secretion have been examined in the human nose. The nasal mucosa is readily accessible musc and, for example, mediator release and microvascular leakage can be measured non-traumatically. A dose of substance P or calcitonin gene related peptide producing systemic vascular effects (vasodilatation) did not induce secretion or nasal blockage and affect mucociliary clearance. Capsaicin, on the other hand, caused a burning sensation, pronounced sneezing, and secretion, patients with vasomotor rhinitis being particularly sensitive. Secretion induced by capsaicin can be blocked by a muscarinic antagonist and is thus due to a cholinergic parasympathetic reflex. Interestingly, capsaicin induced secretion from the human nasal mucosa is also mediated through a cholinergic reflex. Despite administration of capsaicin directly to the nasal mucosa, plasma protein extravasation and mediator release could not be detected.

Interestingly, intradermal injection of capsaicin into human skin produced pain and a local vasodilator response (flare) but not oedema (weal). The flare is produced by sensory neuropeptides released through an axon reflex and, as in the airways, there is little evidence of a local inflammatory response to capsaicin. Tachykinin mediated changes in tracheobronchial and nasal blood flow is, however, a distinct possibility, which has not yet been studied in man.

Thus, whereas studies in rodents strongly emphasise the sensory efferent function of capsaicin sensitive sensory nerves, accumulating data indicate that at least two major effects—that is, bronchoconstriction and extravasation of plasma protein (as measured in the nose)—cannot be reproduced in human subjects. Likewise glandular secretion seems to be mediated via a cholinergic parasympathetic reflex rather than local release of neuropeptides.

Sensory afferent role for capsaicin sensitive nerves in man

Respiratory and cardiovascular reflexes are triggered by topical application of capsaicin. In guinea pigs, example, pronounced coughing and sneezing are produced and these reflexes are mediated by afferent pathways that are separate from those underlying the bronchoconstrictor reflex. Coughing cannot be secondary to release of peptides because these do not themselves trigger cough and treatment with the neutral endopeptidase inhibitor thiorphan did not potentiate the cough response, though bronchoconstriction was increased. Already at low (nanomolar) doses aerosolised capsaicin causes pronounced coughing, sneezing, and secretion in man. Capsaicin induced cough is most probably mediated by tachykinins and C fibre afferents containing calcitonin gene related peptide with endings located in both central and peripheral airways. As in guinea pigs, in man this response seems not to be due to endogenous tachykinins acting on other lung afferents because coughing is not produced from other peptides and, for example, mediator release and microvascular leakage can be measured non-traumatically. It could be argued that coughing prevented the capsaicin aerosol from penetrating deeper into the lung to trigger bronchospasm. Several arguments, however, can be raised against this view. Firstly, in guinea pigs coughing and severe bronchoconstriction occur simultaneously. Secondly, other respiratory tract irritants, such as bradykinin,
produce both cough and airway obstruction in asthmatic subjects. Finally, even when a small particle aerosol is inhaled into peripheral airways no bronchoconstriction is produced.46 Taken together, these findings suggest that the afferent function of capsaicin sensitive nerves in the airways is less species specific, and these nerves are likely to subserve protective reflexes in the human respiratory tract.

**Sensory hyperresponsiveness**

Airway inflammation or chronic irritation with, for example, cigarette smoke may lead to hyperactivity in capsaicin sensitive afferent nerves, as seen in animal experiments. Prolonged exposure (for 14 days) of guinea pigs to cigarette smoke caused an enhanced sensitivity to the tussive effect of citric acid and thus selectively increased the sensitivity and reactivity of capsaicin sensitive nerves mediating cough.47 The airway content of neuropeptides was increased concomitantly,47 but the bronchoconstrictor response was not altered with this treatment. These data indicate that chronic airway irritation may lead to the development of a sensory hyperresponsiveness that is distinct from bronchial hyperresponsiveness. Interestingly, inflammatory stimuli applied to the skin may increase the synthesis of tachykinins in sensory nerves and ganglia,48,49 and in experimental chronic arthritis and inflammatory bowel disease the density of substance P immunoreactive nerves has been reported to be increased.50,51

Clinical observations support the existence of a sensory hyperresponsiveness: subjects with cough induced by angiotensin converting enzyme inhibitor,52 or with a chronic cough,53 as well as subjects with a chronic dry cough,54 have an enhanced responsiveness to the tussive effect of inhaled capsaicin without increased bronchoconstrictor responses. Cough is the most common symptom of airway disease, and in chronic obstructive airway disease and in viral infections of the upper respiratory tract part of the excessive coughing is due to a sensory hyperresponsiveness55 (also RW Fuller, personal communication).

It was recently shown that obstruction, rhinorrhea, and sneezing in patients with non-allergic chronic rhinitis could be significantly reduced after local treatment with capsaicin aerosol that rendered the nerves tachyphylactic.56,57 These clinical findings suggest an important role for tachykinin containing sensory nerves in chronic rhinitis.

Respiratory infections and various forms of sustained irritation of the respiratory tract may lead to neuropeptide synthesis and increased afferent activity with sensory hyperresponsiveness. Sensory hyperresponsiveness may explain some of the symptoms in patients with chronic non-productive cough and non-allergic chronic rhinitis (figure).

**Therapeutic implications**

The hypothesis that capsaicin sensitive sensory neurones may have an important role in reflexes protecting the airway and that chronic irritation may induce sensory hyperresponsiveness has therapeutic implications. At present antimuscarinic drugs, acting postjunctionally, are used to reduce mucus secretion and opiates antitusives to suppress activity in a “cough centre” in the central nervous system. It would be more attractive to inhibit afferent neural activity directly than to inhibit the effects of a range of released neuropeptides. In addition, because different respiratory reflexes have separate afferent neural pathways an improved efficacy and selectivity would be anticipated. Studies in patients with severe, chronic cough support this view: despite several treatments, including the use of high dose opiates, only inhaled local anaesthetics effectively suppressed coughing.58,59 Similarly, induction of tolerance with topical capsaicin inhibited symptoms of chronic rhinitis.60,61 Capsaicin treatment is painful and a drug inhibiting afferent pathways without having agonist activity obviously would be advantageous. It is tempting to suggest that respiratory symptoms during, for example, upper respiratory tract infections or whooping cough would also be reduced by this type of treatment. Afferent neural pathways in the respiratory tract thus provide new targets for rational drug design and possibly such drugs will become useful in the treatment of common illnesses of the respiratory tract.

---

*Sensory hyperresponsiveness* (Diagram showing how irritation of sensory nerves (~ ~ ~) with endings in the human respiratory mucosa evokes protective reflexes. Capsaicin sensitive afferent nerves are carried mainly in the vagal and laryngeal nerves from the tracheobronchial tree and in the trigeminal nerve from the nose. Hyperactivity in sensory nerves, as in chronic non-productive cough and non-allergic chronic rhinitis, may lead to sensory hyperresponsiveness.)
A role for capsaicin sensitive, tachykinin containing nerves in chronic coughing and sneezing but not in asthma: a hypothesis


53 Hanson, L. Midgren B, Simonsson BG. Cough elicited by capsaicin in normal subjects and patients with chronic cough [abstract]. *Bull Eur Physiopathol Respir* 1987; 23(suppl 12):410S.

54 Fuller RW, Choudry NB. Patients with a non-productive cough have an increased cough reflex [abstract]. *Thorax* 1988;43:256.


A role for capsaicin sensitive, tachykinin containing nerves in chronic coughing and sneezing but not in asthma: a hypothesis.

J A Karlsson

Thorax 1993 48: 396-400
doi: 10.1136/thx.48.4.396

Updated information and services can be found at:
http://thorax.bmj.com/content/48/4/396.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/